As per the findings of a retrospective study, admission hyperglycemia is useful to predict Clopidogrel high on-treatment platelet reactivity (HTPR) in people with ischemic stroke. In this study, the relationship between Clopidogrel's HTPR and admission hyperglycemia was explored in ischemic stroke-affected people. Patients with ischemic stroke who received Clopidogrel treatment for at least five days were incorporated.

The platelet function was assessed by thromboelastography. Adenosine diphosphate (ADP)-induced platelet fibrin clot strength (MAADP) > 47 mm was used to identify Clopidogrel HTPR. Otherwise, it would be referred to as normal on-treatment platelet reactivity (NTPR) with clopidogrel. In accordance with earlier studies on admission hyperglycemia, two groups were split based on an admission glucose of 7.8 mmol/L. With the aid of multivariate logistic regression analysis, the independent risk factors for Clopidogrel HTPR were assessed.

Notably, 42 (28.57%) of the 147 individuals who underwent evaluation were recognized as Clopidogrel HTPR. A considerably greater percentage of people (40.38%) were classified as Clopidogrel HTPR in the hyperglycemia arm (admission glucose level ≥7.8 mmol/L) than in the normoglycemia arm (22.11%, admission glucose level<7.8 mmol/L). Multivariate analysis revealed an independent relationship between hyperglycemia and Clopidogrel HTPR (OR=8.36).

Admission glucose level and MAADP had a linear correlation (r=0.29). Additionally, the incidence of Clopidogrel HTPR steadily rose with the rise in admission glucose level tertiles.